Security Snapshot

Kronos Bio, Inc. - Common Stock (KRON) Institutional Ownership

CUSIP: 50107A104

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.87

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

SEC-reported price per share
$0.87
Insider filing price
$0.87
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • KRON - Kronos Bio, Inc. - Common Stock is tracked under CUSIP 50107A104.
  • Latest finished 13F holder period is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • SEC-reported value moved from $16,126 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

50107A104

Latest holder period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
21
Latest
n/a
Rows shown
1-21 of 21
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$16,126 $0.87 0
2025 Q3 16,128 $16,126 +$16,126 $1.00 1
2025 Q2 0 $0 -$15,790,182 $0.87 0
2025 Q1 19,132,784 $15,790,464 -$625,093 $0.82 47
2024 Q4 19,649,673 $18,665,523 -$792,903 $0.95 56
2024 Q3 19,704,103 $19,700,585 -$2,248,644 $1.00 52
2024 Q2 20,645,660 $25,556,191 -$1,590,484 $1.24 55
2024 Q1 21,700,397 $28,231,891 -$6,453,976 $1.30 57
2023 Q4 26,745,874 $33,427,928 -$4,595,965 $1.25 58
2023 Q3 30,266,227 $39,328,312 -$2,264,963 $1.30 63
2023 Q2 31,591,332 $54,317,965 -$1,182,464 $1.72 80
2023 Q1 32,396,272 $47,327,252 -$3,356,353 $1.46 86
2022 Q4 34,494,303 $55,877,865 -$2,972,560 $1.62 94
2022 Q3 36,074,689 $120,851,708 -$3,060,166 $3.35 90
2022 Q2 36,910,104 $134,378,804 -$21,147,007 $3.64 90
2022 Q1 38,994,222 $282,032,437 -$21,840,911 $7.23 91
2021 Q4 41,046,470 $557,830,415 +$1,058,701 $13.59 80
2021 Q3 35,955,919 $753,633,856 -$25,676,168 $20.96 80
2021 Q2 39,757,863 $952,008,187 +$87,935,702 $23.95 76
2021 Q1 33,255,601 $969,057,123 +$55,820,261 $29.27 69
2020 Q4 31,348,530 $928,520,047 +$915,228,048 $29.87 69
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .